Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F17%3A10363517" target="_blank" >RIV/00216208:11140/17:10363517 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/17:10363517

Výsledek na webu

<a href="http://dx.doi.org/10.1016/S2352-3026(17)30168-0" target="_blank" >http://dx.doi.org/10.1016/S2352-3026(17)30168-0</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S2352-3026(17)30168-0" target="_blank" >10.1016/S2352-3026(17)30168-0</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial

Popis výsledku v původním jazyce

Randomised, double-blind, placebo-controlled, phase 3 trial (CONTINUUM), adult patients with chronic lymphocytic leukaemia, who had been treated with two lines of therapy (with at least a partial response after second-line therapy). Between 2009 and 2015, 314 patients were enrolled and randomly assigned to receive either lenalidomide (n=160) or placebo (n=154). Progression-free survival was significantly longer in the lenalidomide group (median 33.9 months, 95% CI 25.5-52.5) than in the placebo group (9.2 months, 7.4-13.6; HR 0.40, 95% CI 0.29-0.55; p&lt;0.0001). The most common grade 3 or 4 adverse events included neutropenia (94 [60%] in the lenalidomide group vs 35 [23%] in the placebo group), thrombocytopenia (26 [17%] vs ten [6%]), and diarrhoea (13 [8%] vs one [&lt;1%]). Chemoimmunotherapy followed by lenalidomide maintenance could be an effective treatment option for patients with chronic lymphocytic leukaemia who do not have access to kinase inhibitors.

Název v anglickém jazyce

Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial

Popis výsledku anglicky

Randomised, double-blind, placebo-controlled, phase 3 trial (CONTINUUM), adult patients with chronic lymphocytic leukaemia, who had been treated with two lines of therapy (with at least a partial response after second-line therapy). Between 2009 and 2015, 314 patients were enrolled and randomly assigned to receive either lenalidomide (n=160) or placebo (n=154). Progression-free survival was significantly longer in the lenalidomide group (median 33.9 months, 95% CI 25.5-52.5) than in the placebo group (9.2 months, 7.4-13.6; HR 0.40, 95% CI 0.29-0.55; p&lt;0.0001). The most common grade 3 or 4 adverse events included neutropenia (94 [60%] in the lenalidomide group vs 35 [23%] in the placebo group), thrombocytopenia (26 [17%] vs ten [6%]), and diarrhoea (13 [8%] vs one [&lt;1%]). Chemoimmunotherapy followed by lenalidomide maintenance could be an effective treatment option for patients with chronic lymphocytic leukaemia who do not have access to kinase inhibitors.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

The Lancet: Haematology

ISSN

2352-3026

e-ISSN

—

Svazek periodika

4

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

"E534"-"E543"

Kód UT WoS článku

000414071900011

EID výsledku v databázi Scopus

2-s2.0-85029900906